|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100051879 |
|
最近更新日期: Date of Last Refreshed on: |
2021-10-09 11:07:14 |
|
注册时间: Date of Registration: |
2021-10-09 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
经阴道腹腔镜下阴道骶骨固定术和传统腹腔镜阴道骶骨固定术的对比:一项随机对照研究 |
|
Public title: |
Comparing Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) sacrocolpopexy and conventional laparoscopic sacrocolpopexy: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
妇科学 |
|
Scientific title: |
Gynecology |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周星楠 |
研究负责人: |
刘娟 |
|
Applicant: |
Xingnan Zhou |
Study leader: |
Juan Liu |
|
申请注册联系人电话: Applicant telephone: |
18820045585 |
研究负责人电话:
Study leader's |
18998321609 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xingnan.zhou@gzhmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
liujuan90011@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市荔湾区多宝路63号 |
研究负责人通讯地址: |
广东省广州市荔湾区多宝路63号 |
|
Applicant address: |
63 Duobao Road, Liwan District, Guangzhou, China |
Study leader's address: |
63 Duobao Road, Liwan District, Guangzhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州医科大学附属第三医院 |
||
|
Applicant's institution: |
The Third Affiliated Hospital of Guangzhou Medical University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
临伦审研备[2020]第056号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属第三医院临床研究与应用伦理委员会 |
||
|
Name of the ethic committee: |
The Third Affiliated Hospital of Guangzhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-07-09 00:00:00 | ||
|
伦理委员会联系人: |
龙土红 |
||
|
Contact Name of the ethic committee: |
Tuhong Long |
||
|
伦理委员会联系地址: |
广东省广州市荔湾区多宝路63号 |
||
|
Contact Address of the ethic committee: |
63 Duobao Road, Liwan District, Guangzhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
广州医科大学附属第三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital of Guangzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市荔湾区多宝路63号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
63 Duobao Road, Liwan District, Guangzhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广州市科学技术局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guangzhou Municipal Science and Technology Bureau |
||||||||||||||||||||||
|
研究疾病: |
盆腔器官脱垂 |
||||||||||||||||||||||
|
Target disease: |
Pelvic organ prolapse |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过随机对照试验(randomized controlled trial,RCT),评估经阴道单孔腹腔镜阴道骶骨固定术的有效性和安全性 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of vNOTES sacrocolpopexy through a randomised controlled trial. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
按照POP定量分度法(POP-Q)分度证实为阴道顶端III度及以上脱垂,且均已完成生育. |
||||||||||||||||||||||
|
Inclusion criteria |
Patients with grade III or more apical prolapses by POP-Q system and no needs for pregnancy any more. |
||||||||||||||||||||||
|
排除标准: |
直肠手术史,怀疑直肠阴道隔子宫内膜异位症或肿瘤,盆腔炎性疾病病史,下生殖道急性感染,无性生活史,怀孕或未签署书面同意书 |
||||||||||||||||||||||
|
Exclusion criteria: |
History of rectal surgery, suspected rectovaginal endometriosis or malignancy, history of pelvic inflammatory disease, active lower genital tract infection, virginity, pregnancy or failure to provide written informed content. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-04-01 00:00:00至 To 2023-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-04-01 00:00:00 至 To 2023-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
电脑产生随机序列,研究秘书负责按照随机信封分配患者入组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
All participants will be randomly assigned to the two groups using a computer-generated randomization schedule. The study secretary will generate the allocation sequence and assign the participants to one of both interventions. Sequentially numbered, opaque, sealed envelopes will be used to ensure allocation concealment. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2024年12月, ResMan, http://www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
December 2024,ResMan, http://www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
Excel和EpiData |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Excel and EpiData |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |